Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
NCT07144527
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Aging
- Frailty
- Exercise Tolerance
- Healthy Male and Female Subjects
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 60 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Scott Silveira
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Medical Office of Dr. Robert Huizenga MD · Beverly Hills, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.